Verona Pharma plc (VRNA) Announces Additional Commercialization Team Appointments Aug 24, 2022 05:18AM
Verona Pharma strengthens commercialization leadership team Aug 24, 2022 02:00AM
Nuance Pharma receives Clearance to begin Pivotal Clinical Trials with Ensifentrine for COPD in China Aug 19, 2022 02:46AM
Verona Pharma plc Announces Closing of Upsized Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional ADSs Aug 15, 2022 04:05PM
Verona Pharma plc (VRNA) Pricing Upsized 12.4M Share Offering at $10.50/sh Aug 11, 2022 05:35AM
View Older Stories

Aug 10, 2022 08:22PM Verona Pharma plc Announces Pricing of Upsized Underwritten Public Offering
Aug 9, 2022 04:19PM Verona Pharma plc (VRNA) Announces Proposed Stock Offering
Aug 9, 2022 04:16PM Verona Pharma plc Announces Proposed Underwritten Public Offering
Aug 9, 2022 06:24AM Verona Pharma plc (VRNA) Reports Ensifentrine Meets Primary Endpoint in Phase 3 ENHANCE-2 Trial
Aug 9, 2022 03:00AM Verona Pharma Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Aug 9, 2022 02:00AM Verona Pharma Announces Ensifentrine Meets Primary Endpoint in Phase 3 ENHANCE-2 Trial for COPD
Aug 8, 2022 04:30PM Verona Pharma to Announce Top-line Data from Phase 3 ENHANCE-2 Trial of Nebulized Ensifentrine for COPD
Jul 29, 2022 02:00AM Verona Pharma to Report Second Quarter 2022 Financial Results and Provide Corporate Update
Jun 9, 2022 02:00AM Verona Pharma Completes Enrollment in Phase 3 ENHANCE-1 Trial Evaluating Ensifentrine for Maintenance Treatment of COPD
Jun 6, 2022 02:00AM Verona Pharma to Host KOL Event on June 16, 2022
May 25, 2022 02:00AM Verona Pharma to Present at Jefferies Healthcare Conference
May 9, 2022 02:00AM Verona Pharma to Present Successful TQT Analysis Demonstrating No Clinically Relevant Effect on Cardiac Conduction at the American Thoracic Society 2022
May 4, 2022 02:00AM Verona Pharma Announces May 2022 Investor Conference Participation
May 3, 2022 05:55AM Verona Pharma plc (VRNA) Reports Q1 Results, Provides Corporate Update
May 3, 2022 02:00AM Verona Pharma Reports First Quarter 2022 Financial Results and Provides Corporate Update
Apr 19, 2022 02:00AM Verona Pharma to Report First Quarter 2022 Financial Results and Provide Corporate Update
Mar 14, 2022 03:00AM James Brady Joins Verona Pharma as Non-Executive Director
Mar 3, 2022 02:00AM Verona Pharma Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
Feb 17, 2022 02:00AM Verona Pharma to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update
Jan 24, 2022 02:00AM Verona Pharma Completes Enrollment in Phase 3 ENHANCE-2 Trial Evaluating Ensifentrine for Maintenance Treatment of COPD
Jan 5, 2022 02:00AM Verona Pharma Completes Enrollment in ENHANCE-1 48-week Subset
Jan 4, 2022 02:00AM Verona Pharma to Present at H.C. Wainwright BioConnect Virtual Conference
Dec 16, 2021 05:57AM Verona Pharma plc (VRNA) Reports TQT Study Successfully Demonstrated No Clinically Relevant Effect on Cardiac Conduction
Dec 16, 2021 02:00AM Verona Pharma Reports TQT Study Successfully Demonstrated No Clinically Relevant Effect on Cardiac Conduction
Nov 9, 2021 02:00AM Verona Pharma Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Nov 1, 2021 03:00AM Verona Pharma Announces November 2021 Investor Conference Participation
Oct 26, 2021 02:00AM Verona Pharma to Report Third Quarter 2021 Financial Results and Provide Corporate Update
Oct 13, 2021 02:00AM Verona Pharma to Present Phase 2 Data with pMDI Ensifentrine in COPD at CHEST 2021
Sep 2, 2021 02:00AM Verona Pharma Presents Pharmacokinetic Data with Ensifentrine at the European Respiratory Society International Congress 2021
Aug 31, 2021 02:00AM Verona Pharma to Present at H.C. Wainwright 23rd Annual Global Investment Conference
Aug 5, 2021 02:00AM Verona Pharma Reports Second Quarter 2021 Financial Results and Provides Corporate Update
Jul 27, 2021 02:00AM Verona Pharma Announces August 2021 Virtual Investor Conference Participation
Jul 22, 2021 02:00AM Verona Pharma to Report Second Quarter 2021 Financial Results and Provide Corporate Update
Jun 10, 2021 02:00AM Verona Pharma and Nuance Pharma Announce $219 Million Strategic Collaboration to Develop and Commercialize Ensifentrine in Greater China
May 25, 2021 02:00AM Verona Pharma to Present at Jefferies Virtual Healthcare Conference
May 4, 2021 02:00AM Verona Pharma to Present Expanded Analysis of Phase 2b COPD Data with Ensifentrine at the American Thoracic Society 2021 International Conference
Apr 29, 2021 02:00AM Verona Pharma Reports First Quarter 2021 Financial Results and Provides Corporate Update
Apr 27, 2021 05:55AM Verona Pharma plc (VRNA) Reports Publication of Phase 2b Dose-Ranging COPD Data
Apr 27, 2021 02:00AM Verona Pharma Announces Publication of Phase 2b Dose-Ranging COPD Data in the International Journal of Chronic Obstructive Pulmonary Disease
Apr 23, 2021 02:00AM Verona Pharma Reports Results of Pilot Study of pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19
Apr 21, 2021 02:00AM Verona Pharma to Report First Quarter 2021 Financial Results and Provide Corporate Update
Mar 2, 2021 02:00AM Lisa Deschamps Joins Verona Pharma as Non-Executive Director
Mar 1, 2021 02:00AM Verona Pharma to Present at H.C. Wainwright Global Life Sciences Virtual Conference
Feb 25, 2021 02:00AM Verona Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
Feb 18, 2021 02:00AM Verona Pharma to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update
Feb 2, 2021 06:17AM CORRECTING and REPLACING -- Verona Pharma Reports Positive Phase 2 Results with pMDI Formulation of Ensifentrine in COPD
Feb 2, 2021 06:17AM CORRECTING and REPLACING -- Verona Pharma Reports Positive Phase 2 Results with pMDI Formulation of Ensifentrine in COPD
Feb 2, 2021 05:55AM Verona Pharma plc (VRNA) Announces Positive Phase 2 Results with pMDI Formulation of Ensifentrine in COP
Feb 2, 2021 02:00AM Verona Pharma Reports Positive Phase 2 Results with pMDI Formulation of Ensifentrine in COPD
Feb 2, 2021 02:00AM Verona Pharma Reports Positive Phase 2 Results with pMDI Formulation of Ensifentrine in COPD
View Older Stories